Abdulaziz A. Alsheikh has been co-founder and managing director of Spectropharma, a Saudi company established to research, manufacture and market pharmaceutical and biosimilar products, since May 2021.
Spectropharma is in the process of developing a state-of-the-art manufacturing facility in Sudair Industrial City, 120 km northeast of Riyadh, designed to produce quality medicines for the Kingdom and export markets.
Alsheikh is a leading figure in the healthcare industry in the Gulf Cooperation Council region, and has held various leadership roles during the past 23 years.
In his long and illustrious career, Alsheikh is widely acknowledged for his transformational leadership and breakthrough commercial performances. While creating high-performance organizations, Alsheikh has maintained equal focus on creating warm, inclusive, and collaborative work cultures. He works persistently to further improve the healthcare industry in the Kingdom, along with supporting various social causes.
Prior to Spectropharma, he served as general manager of J&J Medical Device, Janssen Pharma from April 2015 to May 2021 and earlier led as the general manager of Banaja Medical Co., Banaja Holdings, between January 2008 and May 2015.
He was a country manager of LifeScan J&J between September 2004 and December 2007. Between 2002 and 2004, he was sales and product manager at Merck & Co., and also worked at Whitehouse Station, New Jersey, US. He also serves on the boards of some leading corporations and served as chairman of Korn Ferry International between August 2008 and May 2011 where he was entrusted with providing strategic leadership to transform Korn Ferry into the Kingdom’s leading executive recruitment firm.
Alsheikh is a chemical engineer by training, attending King Saud University in Riyadh, and earned his MBA from the American University in Washington, DC.
